PALOMA-2: Addition of Palbociclib to Frontline Letrozole Significantly Improves PFS in Postmenopausal ER+/HER2- Advanced Breast Cancer CCO Independent. - ppt download
Endocrine Combinations in HR-Positive MBC: The Future Is Now - ppt download
Progression-free survival in the PALOMA-1 study (palbociclib +... | Download Scientific Diagram
IBRANCE® (palbociclib) + an AI | Preplanned PFS Analyses | Safety Info
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study ...
Palbociclib in ER+ Breast Cancer - Breast Cancer - 2016 American Society of Clinical Oncology Annual Meeting - Oncology - Clinical Care Options
Palbociclib and Letrozole in Advanced Breast Cancer | NEJM
Progression-free survival (PFS) in the PALOMA-1 phase II trial... | Download Scientific Diagram
Palbociclib and Letrozole in Advanced Breast Cancer | NEJM
Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical trials | SpringerLink
Palbociclib and Letrozole in Advanced Breast Cancer | NEJM
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study ...
Progression-free Survival Outcome Is Independent of Objective Response in Patients With Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer Treated With Palbociclib Plus Letrozole Compared With Letrozole ...
Palbociclib plus endocrine therapy in older women with HR+/HER2– advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies - European Journal of Cancer
Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial - Annals of Oncology
Clinical Trial Summary | IBRANCE® (palbociclib) | Safety Info
MONALEESA clinical program: a review of ribociclib use in different clinical settings | Future Oncology
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind ...
Concordance of real-world versus conventional progression-free survival from a phase 3 trial of endocrine therapy as first-line treatment for metastatic breast cancer | PLOS ONE
Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18) | SpringerLink
Figure 2 from PALOMA-3: Phase III Trial of Fulvestrant With or Without Palbociclib in Premenopausal and Postmenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That Progressed
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer | NEJM
Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18) | SpringerLink
Palbociclib and Letrozole in Advanced Breast Cancer | NEJM
Real-World Overall Survival | IBRANCE® (palbociclib) | Safety Info
IBRANCE® (palbociclib) + an AI | Updated PFS Analyses | Safety Info
Efficacy and safety of palbociclib in patients with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer with preexisting conditions: A post hoc analysis of PALOMA-2 - The Breast
Palbociclib plus endocrine therapy in older women with HR+/HER2– advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies - European Journal of Cancer
